Special Issue

Hepatitis B Virus (HBV) Infection and Vaccine

Message from the Guest Editor

According to The Institut Pasteur data, hepatitis B is one of the most prevalent human diseases. It is estimated that two billion people have been infected by the virus. Chronic infection with hepatitis B virus (HBV) develops in millions of patients every year, despite the availability of effective prophylactic vaccines that can prevent hepatitis B. Chronic carriers have a high risk of dying from cirrhosis or liver cancer. These diseases cause about 887,000 deaths annually. The existing vaccines have proven to be highly effective in preventing HBV infection, but ongoing research aims to improve their efficacy, duration of protection, and accessibility. These vaccines are less effective in certain groups of people such as aged and obese people or are ineffective in chronic HBV carriers. Therefore, the Special Issue aims to provide a collection of articles that highlight recent advancements in the field of hepatitis B. As the of this Special Issue, I invite you to submit research articles, review articles, and short communications related to Hepatitis B infection as well as to prophylactic and therapeutic vaccine development against this virus.

Guest Editor

Dr. Irina Sominskaya

Latvian Biomedical Research and Study Centre, Ratsupites 1, LV-1067 Riga, Latvia

Deadline for manuscript submissions

closed (31 March 2025)

Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/198811

Microorganisms
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
microorganisms@mdpi.com

mdpi.com/journal/microorganisms

Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/microorganisms

About the Journal

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Editor-in-Chief

Dr. Nico Jehmlich
Department of Molecular Toxicology, UFZ-Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).

MDPI